Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis

Journal of the American College of Cardiology

Volumn 47, Issue 7, 2006, Pages 1471-1477

  Lewis, Gregory D ^a   Witzke, Christian ^a   Colon Hernandez, Pedro ^a   Guerrero, J Luis ^a   Bloch, Kenneth D ^a   Semigran, Marc J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; HEPARIN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DOG; DRUG BLOOD LEVEL; ENDOTHELIUM INJURY; EXPERIMENTAL MODEL; HEART INFARCTION; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STENOSIS; THROMBOCYTE COUNT; THROMBOGENESIS; VASCULAR PATENCY;

ANIMALS; ASPIRIN; BLOOD COAGULATION; BLOOD PRESSURE; CORONARY CIRCULATION; CORONARY THROMBOSIS; CORONARY VESSELS; DOGS; FIBRINOLYTIC AGENTS; HEART RATE; HEPARIN; PERIODICITY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLATELET AGGREGATION; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 33645384653     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.11.060     Document Type: Article

References (39)

1. V. Fuster, L. Badimon, J.J. Badimon The pathogenesis of coronary artery disease and the acute coronary syndromes N Engl J Med 326 1992 242 250
2. L.Y. Chen, W.W. Nichols, C. Mattsson, A.-C. Teger-Nilson, R. Wallin, T.G.P. Saldeen, J.L. Mehta Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis Cardiovasc Res 30 1995 866 874
3. S. Matetzky, B. Shenkman, V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
4. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes N Engl J Med 339 1998 436 443
5. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
6. C.P. Cannon, W.S. Weintraub, L.A. Demopoulos Comparison of early invasive vs conservative strategies in patients with unstable angina and non-ST elevation myocardial infarction treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 2001 1879 1887
7. J.D. Rovin, J.S. Stamler, J. Loscalzo, J.D. Folts Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries J Cardiovasc Pharmacol 22 1993 626 631
8. R.J. Haslam, N.T. Dickinson, E.K. Jang Cyclic nucleotides and phosphodiesterases in platelets Thromb Haemost 82 1999 412 423
9. J. Tremblay, R. Gerzer, P. Hamlet Cyclic GMP in cell function Adv Second Messenger Phosphoprotein Res 22 1988 319 383
10. T.M. Chiang, S.N. Dixit, A.H. Kang Effect of cyclic 3′,5′- guanosine monophosphate on human platelet function J Lab Clin Med 68 1976 215 221
11. Z. Li, X. Xi, M. Gu A stimulatory role for cGMP-dependent protein kinase in platelet activation Cell 112 2003 77 86
12. M.L. Steer, E.W. Salzman Cyclic nucleotides in hemostasis and thrombosis Adv Cyclic Nuclotide Res 12 1980 71 92
13. S. Gambaryan, J. Geiger, U.R. Schwarz Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase Blood 103 2004 2593 2600
14. R.M. Wallis, J.D. Corbin, S.H. Francis Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro Am J Cardiol 83 1999 3C 12C
15. U. Schmidt, R.O. Han, T.G. DiSalvo Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition J Am Coll Cardiol 37 2001 1981 1988
16. S.A. Ballard, C.J. Gingell, K. Tang, L.A. Turner, M.E. Price, A.M. Naylor Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes J Urol 159 1998 2164 2171
17. C. Adrie, K.D. Bloch, P.R. Moreno Inhaled nitric oxide increases coronary artery patency after thrombolysis Circulation 94 1996 1919 1926
18. H.K. Gold, T. Yasuda, I.K. Jang Animal models for arterial thrombolysis and prevention of reocclusion erythrocyte-rich versus platelet-rich thrombus Circulation 83 Suppl IV 1991 IV26 IV40
19. G.J. Muirhead, D.J. Rance, D.K. Walker, P. Wastall Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil Br J Clin Pharmacol 53 2002 13s 20s
20. J.D. Cooper, D.C. Muirhead, J.E. Taylor, P.R. Baker Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography J Chromatogr B 701 1997 87 95
21. J.A. Beavo, D.H. Reifsnyder Primary sequence of cyclic nucleotide phosphodiesterase enzymes and the design of selective inhibitors Trends Pharmacol Sci 11 1990 150
22. A.A. Ziskind, H.K. Gold, T. Yasuda Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator Circulation 79 1989 393 399
23. T. Yasuda, H.K. Gold, H. Yaoita Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation J Am Coll Cardiol 16 1990 714 722
24. H.C. Herrmann, G. Chang, B.D. Klugherz, P.D. Mahoney Hemodynamic effects of sildenafil in men with severe coronary artery disease N Engl J Med 342 2000 1622 1626
25. D.A. Tulis, K.S. Bohl Masters, E.A. Lipke YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function Biochem Biophys Res Commun 291 2002 1014 1021
26. J.P. Stasch, C. Alonso-Alija, H. Apeler Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543 in vitro studies Br J Pharmacol 135 2002 333 343
27. A.J. Hobbs, S. Moncada Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272 Vasc Pharmacol 40 2003 149 154
28. S. Vemulapalli, P.J. Chiu, S. Kurowski In vivo inhibition of platelet adhesion by a cGMP-mediated mechanism in balloon catheter injured rat carotid artery Pharmacology 52 1996 235 242
29. R. Berkels, T. Klotz, G. Sticht Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil J Cardiovasc Pharmacol 37 2001 413 421
30. R.A. Kloner, R.M. Zusman Cardiovascular effects of sildenafil citrate and recommendations for its use Am J Cardiol 84 1999 11N 17N
31. M.K. Thomas, S.H. Francis, J.D. Corbin Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase J Biol Chem 265 1990 14964 14970
32. G.A. Fitzgerald Dipyridamole N Engl J Med 316 1987 1247 1257
33. K. Przyklenk, R.A. Kloner Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis J Am Coll Cardiol 37 2001 286 292
34. R.R. Arora, M. Timoney, L. Melilli Acute myocardial infarction after the use of sildenafil N Engl J Med 341 1999 700
35. M. Mitka Some men who take Viagra die - why? JAMA 283 2000 590 593
36. M.A. Mittleman, D.B. Glasser, J. Orazem Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo Int J Clin Pract 57 2003 597 600
37. D.K. Wysowski, E. Farinas, L. Swartz Comparison of reported and expected deaths in sildenafil (Viagra) users Am J Cardiol 89 2002 1331 1334
38. J.P.J. Halcox, K.R.A. Nour, G. Zalos The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia J Am Coll Cardiol 40 2002 1232 1240
39. E.D. Michelakis, W. Tymchak, M. Noga Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension Circulation 108 2003 2066 2069